1.
JAMA
; 332(1): 74-76, 2024 07 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38842823
RESUMO
This study examines formulary coverage of brand-name adalimumab and biosimilars across Medicare Part D plans.